June 18, 2026
2 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
In a Healio video exclusive, Edward V. Loftus Jr., MD, discusses lingering questions on the potential risks that gender-affirming hormone therapy may have for transgender patients with inflammatory bowel disease.
June 18, 2026
2 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Evidence suggests inflammatory bowel disease is equally prevalent in transgender and cisgender populations. However, it remains…

CHICAGO — In this video, Chandler S. Cortina, MD, MS, FACS, discusses a cohort study that highlights the importance of additional…

LAS VEGAS — LGBTQ+ individuals with inflammatory bowel disease experience multiple gaps and inequities in care when managing…

HHS is requesting changes to prescribing information for testosterone therapy products following a review of new clinical data…

Most gynecologic oncologists and radiation oncologists would consider prescribing hormone therapy for patients with cervical…

CHICAGO — Most men who received testosterone therapy did not receive a workup in accordance with guidelines, and some received…